Table 3.

Association of Biomarker Levels With cGVHD in Verification Cohort 2 (87 patients and 93 controls)

Model	OR* (95% CI)	P	AUC†
Single biomarkers
ST2	4.77 (2.0 to 11.6)	< .001	0.67
CXCL9	2.69 (1.5 to 5.0)	< .001	0.64
MMP3	3.36 (1.7 to 6.7)	.003	0.66
OPN	1.31 (0.4 to 4.6)	.66	0.53
Combination of biomarkers
ST2	4.29 (1.5 to 12.2)	< .001	0.75
CXCL9	3.48 (1.8 to 6.9)
MMP3	2.45 (1.1 to 5.5)
OPN	0.35 (0.1 to 1.6)
Single biomarkers with clinical covariates‡
ST2	3.76 (1.2 to 11.5)	.02	0.76
CXCL9	3.81 (1.9 to 7.7)	< .001	0.79
MMP3	1.97 (0.9 to 4.4)	.09	0.76
OPN	0.99 (0.2 to 4.2)	.98	0.74
Combination of biomarkers with clinical covariates‡
ST2	4.19 (1.2 to 14.4)	< .001	0.82
CXCL9	4.47 (2.1 to 9.5)
MMP3	1.69 (0.7 to 4.0)
OPN	0.40 (0.1 to 2.0)

Abbreviations: AUC, area under the curve; cGVHD, chronic graft-versus-host disease; OR, odds ratio.

^*OR per log increase in biomarker, estimated using logistic regression.

^†AUC calculated from logistic regression; includes clinical covariates in model where indicated

^‡AUC with clinical covariates only: 0.74.